Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

105P - Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): single arm phase II study

Date

08 Dec 2022

Session

Poster Display

Presenters

Peng Jin

Citation

Annals of Oncology (2022) 16 (suppl_1): 100102-100102. 10.1016/iotech/iotech100102

Authors

P. Jin1, Y. Gao2, Z. Fu2, W. Yang2, X. Meng2

Author affiliations

  • 1 Shandong Cancer Hospital Affiliated to Shandong University, Jinan/CN
  • 2 Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 105P

Background

This study aimed to evaluate the safety and efficacy of neoadjuvant tislelizumab combined with chemoradiotherapy in patients with resectable esophageal squamous cell cancer.

Methods

This is a prospective single-arm clinical trial. A total of 19 patients with newly diagnosed resectable esophageal cancer (cT1-2N+ / cT3-4aN0-3 M0) received 2 cycles of tislelizumab (200mg every 3 weeks for 2 cycles) concurrent with chemoradiotherapy (radiotherapy: 41.4Gy in 23 fractions; chemotherapy: Paclitaxel (Albumin bound) 100mg/m2, and Cisplatin 75 mg/m2 once every 3 weeks for 2 cycles.) Radical esophagectomy was performed within 4-6 weeks after neoadjuvant therapy. PET/CT was performed at baseline and before surgery. Primary endpoints included pathological response rate (pCR) and major pathological response rate (MPR), the secondary endpoints were disease free survival and safety. Exploratory endpoints include molecular imaging research to further explore the factors affecting the efficacy of neoadjuvant therapy for esophageal cancer.

Results

Nineteen patients enrolled, all of whom received neoadjuvant tislelizumab combined with chemoradiotherapy. Seventeen patients underwent radical esophagectomy. One patient did not undergo radical chemoradiotherapy due to lymph node metastases after neoadjuvant therapy. One patient died of pneumonia before surgery. Among 17 patients who underwent surgery, R0 was 100% (17/17), 8 patients achieved pCR (47.1%), and 12 patients achieved MPR (70.6%). Most of treatment-related adverse event (TRAE) were grade 1-2, and the most common TRAE was anemia (15, 78.9%). The grade 3 TRAE included 1 leukopenia (5.3%), 1 neutropenia (5.3%), 1 liver damage (5.3%), and 1 elevated cardiac troponin T (5.3%). A significant decrease in SUVmax was observed in both pCR and no-pCR patients after treatment. Baseline SUVmax in no-pCR patients tended to be higher than pCR patients(p=0.0642).

Conclusions

Neoadjuvant tislelizumab combined with chemoradiotherapy for locally advanced ESCC has promising efficacy and good safety.

Clinical trial identification

NCT05323890.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.